HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindström, T. Articles by Arnqvist, H. J. Search for Related Content PubMed PubMed Citation Articles by Lindström, T. Articles by Arnqvist, H. J. Social Bookmarking                What's this?

Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs

¹ Division of Internal Medicine, Department of Medicine and Care
² Division of Cellbiology, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping University, Linköping, Sweden

OBJECTIVE—To measure the contribution of bedtime intermediate-acting human insulin on the morning plasma insulin profiles after injection of the rapid-acting insulin analogs lispro and aspart in patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS—A total of 14 patients with type 1 diabetes, aged 35 ± 13 years (mean ± SD), participated in this single-blind, randomized crossover study. After taking their usual injection of human intermediate-acting insulin the night before, they were given insulin aspart or insulin lispro (10 units) before a standardized breakfast. The contribution of continuing absorption of the human insulin was measured using a monoclonal antibody not cross-reacting with insulin aspart or lispro, whereas the contribution of the analogs was estimated by subtraction after measurement of all plasma free insulin using an antibody cross-reacting equally with human insulin and both analogs.

RESULTS—The correlation coefficient of the fasting free insulin concentrations measured with both insulin methods was 0.95. Fasting free insulin was 95 ± 25 pmol/l before administration of insulin aspart, when determined with enzyme-linked immunosorbent assay detecting only human insulin, and 71 ± 20 pmol/l before administration of insulin lispro (NS). Both insulin analogs gave marked peaks of free insulin concentrations, lispro at 40 ± 3 min and aspart at 55 ± 6 min after injection (P = 0.01). The later part of the profiles, from 4.5 to 5.5 h after injection, were similar and showed almost no contribution of the insulin analogs.

CONCLUSIONS—The combination of insulin assays that detect human insulin only or both human insulin and analogs provides a new tool for studying insulin pharmacokinetics. Using this technique, we showed that 4.5 h after administration of the rapid-acting insulin analogs lispro and aspart, the free insulin levels are almost only attributable to the intermediate-acting insulin given at bedtime.

Abbreviations: AUC, area under the curve • ELISA, enzyme-linked immunosorbent assay

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A Alidibbiat, C E Marriott, K T Scougall, S C Campbell, G C Huang, W M Macfarlane, and J A M Shaw Inability to process and store proinsulin in transdifferentiated pancreatic acinar cells lacking the regulated secretory pathway J. Endocrinol., January 1, 2008; 196(1): 33 - 43. [Abstract] [Full Text] [PDF]

				U. Hiden, E. Glitzner, M. Ivanisevic, J. Djelmis, C. Wadsack, U. Lang, and G. Desoye MT1-MMP Expression in First-Trimester Placental Tissue Is Upregulated in Type 1 Diabetes as a Result of Elevated Insulin and Tumor Necrosis Factor-{alpha} Levels Diabetes, January 1, 2008; 57(1): 150 - 157. [Abstract] [Full Text] [PDF]

				U.-B. Johansson, S. Amsberg, L. Hannerz, R. Wredling, U. Adamson, H. J. Arnqvist, and P.-E. Lins Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites Diabetes Care, August 1, 2005; 28(8): 2025 - 2027. [Full Text] [PDF]

				W. E. Owen and W. L. Roberts Cross-Reactivity of Three Recombinant Insulin Analogs with Five Commercial Insulin Immunoassays Clin. Chem., January 1, 2004; 50(1): 257 - 259. [Full Text] [PDF]

				J. Plank, A. Wutte, G. Brunner, A. Siebenhofer, B. Semlitsch, R. Sommer, S. Hirschberger, and T. R. Pieber A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes Diabetes Care, November 1, 2002; 25(11): 2053 - 2057. [Abstract] [Full Text] [PDF]